Rodman & Renshaw analyst Raghuram Selvaraju views the FDA advisory committee vote in favor of brodalumab as a meaningful positive for Valeant that substantially increases the likelihood of approval for the drug later this year. Though brodalumab doesn't have blockbuster potential in the U.S., it could generate $400M-$500M in peak U.S. sales if approved, even with a black box warning, believes Selvaraju. On the heels of this panel vote and the FDA approval of the supplemental New Drug Application for oral Relistor, Valeant may potentially get approval of Vesneo for glaucoma later this week, said the analyst, who keeps a Buy rating and $90 price target on Valeant shares.